Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated ...

The controversial drugs are not yet approved, but advocates hope a NC law would allow the state to be ready, should the FDA approve them.

A surprising discovery from Emory University shows that psilocin, the active metabolite of psychedelic mushrooms, can delay ...

Regulators plan to integrate ibogaine treatment into Colorado’s psychedelic healing industry. Still, the drug faces an uncertain future.

The pace of quarterly reports is stiffening and in the main, like a lamington, the news is easy to digest for ASX biotech investors.

Psilocybin has slowed down the aging process in cells and mice. It may be able to scale up to humans and help slow diseases ...

Supporters believe that FDA approval will make the drug more accessible. Right now, traditional psilocybin therapy offered at healing centers in the state is not covered by insurance.

Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways ...

President Petr Pavel has signed a bill on July 17th that decriminalizes recreational cannabis for personal use and home ...

With no clear rules from health or drug authorities, thousands of businesses openly sell psilocybin mushrooms even though the ...

In a new study published this month in npj Aging, researchers report that psilocybin slowed down key aspects of the aging ...